Cardiorenal Research Laboratory, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Cardiorenal Research Laboratory, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota; Division of Clinical Medicine, Department of Medicine and Surgery, University of Parma, Parma, Italy.
JACC Heart Fail. 2019 Oct;7(10):891-898. doi: 10.1016/j.jchf.2019.05.012. Epub 2019 Sep 11.
This study investigated the differential regulation of circulating atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in patients with acute decompensated heart failure (ADHF) and tested the hypothesis that a relative deficiency of ANP exists in a subgroup of patients with ADHF.
The endocrine heart releases the cardiac hormones ANP and BNP, which play a key role in cardiovascular (CV), renal, and metabolic homeostasis. In heart failure (HF), both plasma ANP and BNP are increased as a compensatory homeostatic response to myocardial overload.
ANP and BNP concentrations were measured in a small group of patients with ADHF (n = 112). To support this study's goal, a total of 129 healthy subjects were prospectively recruited to establish contemporary normal values for ANP and BNP. Plasma 3',5'cyclic guanosine monophosphate (cGMP), ejection fraction (EF), and body mass index (BMI) were measured in these subjects.
In cases of ADHF, 74% of patients showed elevated ANP and BNP. Importantly, 26% of patients were characterized as having normal ANP (21% of this subgroup had normal ANP and elevated BNP). Cyclic GMP was lowest in the ADHF group with normal levels of ANP (p < 0.001), whereas BMI and EF were inversely related to ANP levels (p = 0.003).
Among a subgroup of patients hospitalized with ADHF, the presence of an ANP deficiency is consistent with a differential regulation of ANP and BNP and suggests the existence of a potentially compromised compensatory cardiac endocrine response. These findings have implications for the pathophysiology, diagnostics, and therapeutics of human HF.
本研究旨在探讨急性失代偿性心力衰竭(ADHF)患者循环心房利钠肽(ANP)和 B 型利钠肽(BNP)的差异调节,并验证 ANP 相对缺乏存在于 ADHF 亚组患者的假设。
内分泌心脏释放心脏激素 ANP 和 BNP,它们在心血管(CV)、肾脏和代谢稳态中发挥关键作用。在心力衰竭(HF)中,由于心肌超负荷的代偿性稳态反应,血浆 ANP 和 BNP 均增加。
对一小部分 ADHF 患者(n=112)测量了 ANP 和 BNP 浓度。为了支持本研究的目标,前瞻性招募了总共 129 名健康受试者,以确定 ANP 和 BNP 的当代正常值。这些受试者测量了血浆 3',5'环鸟苷单磷酸(cGMP)、射血分数(EF)和体重指数(BMI)。
在 ADHF 病例中,74%的患者表现出升高的 ANP 和 BNP。重要的是,26%的患者表现出正常的 ANP(该亚组中有 21%的患者具有正常的 ANP 和升高的 BNP)。在 ANP 水平正常的 ADHF 组中,cGMP 最低(p<0.001),而 BMI 和 EF 与 ANP 水平呈反比(p=0.003)。
在因 ADHF 住院的亚组患者中,ANP 缺乏的存在与 ANP 和 BNP 的差异调节一致,并表明存在潜在受损的代偿性心脏内分泌反应。这些发现对人类 HF 的病理生理学、诊断和治疗具有重要意义。